These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32224679)

  • 21. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
    Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE
    Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Complete remission of Loeffler's endocarditis with Imatinib in a myeloid and lymphoid neoplasm associated with eosinophilia].
    Wienemann H; Bröckelmann PJ; Adam M
    Dtsch Med Wochenschr; 2020 Jan; 145(1):36-39. PubMed ID: 31914467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Sustained hematologic response in chronic eosinophilic leukemia with low dose imatinib. Report of one case].
    Torres C D; Chandía M
    Rev Med Chil; 2014 Apr; 142(4):516-20. PubMed ID: 25117044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib].
    Verstappen MC; Mattijssen V; van der Reijden BA; van der Heijden AJ; Wahab PJ; de Vries RA
    Ned Tijdschr Geneeskd; 2006 May; 150(21):1188-92. PubMed ID: 16768284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
    Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
    N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
    Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
    Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.
    Cools J; Stover EH; Wlodarska I; Marynen P; Gilliland DG
    Curr Opin Hematol; 2004 Jan; 11(1):51-7. PubMed ID: 14676627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
    Cools J
    Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
    Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
    Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy].
    Sekkach Y; Mekouar F; Jira M; Elqatni M; Elomri N; Fatihi J; Badaoui M; Hammi S; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
    Ann Pharm Fr; 2011 Sep; 69(5):277-81. PubMed ID: 21924129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cough in hypereosinophilic syndrome: case report and literature review.
    Xie J; Zhang J; Zhang X; Zhang Q; Chung KF; Wang C; Lai K
    BMC Pulm Med; 2020 Apr; 20(1):90. PubMed ID: 32293378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
    Coutré S; Gotlib J
    Semin Cancer Biol; 2004 Aug; 14(4):307-15. PubMed ID: 15305431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
    Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
    Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate.
    Tashiro H; Shirasaki R; Noguchi M; Gotoh M; Kawasugi K; Shirafuji N
    Int J Hematol; 2006 Jun; 83(5):433-8. PubMed ID: 16787876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imatinib responsive erythrocytosis in a patient with FIP1L1::PDGFRA rearranged myeloid neoplasm with hypereosinophilia - Another manifestation of a stem cell neoplasm.
    Virk H; Rathore S; Anshu A; Jamwal M; Lad D; Das R; Sreedharanunni S
    Leuk Res; 2022 Oct; 121():106922. PubMed ID: 35933911
    [No Abstract]   [Full Text] [Related]  

  • 36. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.
    Elling C; Erben P; Walz C; Frickenhaus M; Schemionek M; Stehling M; Serve H; Cross NC; Hochhaus A; Hofmann WK; Berdel WE; Müller-Tidow C; Reiter A; Koschmieder S
    Blood; 2011 Mar; 117(10):2935-43. PubMed ID: 21224473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of FIP1L1-PDGFRA fusion gene-positive cells in the skin lesion of a patient with hypereosinophilic syndrome.
    Kitayama S; Makino T; Yoto A; Mori S; Furukawa F; Torai R; Mizawa M; Shimizu T
    Clin Exp Dermatol; 2023 Mar; 48(4):364-367. PubMed ID: 36763740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of hypereosinophilic syndrome presenting with chronic cough successfully treated with imatinib.
    Kobayashi M; Kubota T; Uemura Y; Taguchi H
    Respirology; 2009 Mar; 14(2):302-4. PubMed ID: 19192229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
    Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
    Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene.
    Yoshida M; Tamagawa N; Nakao T; Kanashima H; Ueda H; Murakami A; Yorifuji T; Yamane T
    Leuk Lymphoma; 2015 Mar; 56(3):768-9. PubMed ID: 24975316
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.